Terms: = Leukemia AND RECQL4, RecQ4, 9401, ENSG00000160957, RECQ4, RTS AND Treatment
12 results:
1. Enrichment of heterozygous germline
Maciaszek JL; Oak N; Chen W; Hamilton KV; McGee RB; Nuccio R; Mostafavi R; Hines-Dowell S; Harrison L; Taylor L; Gerhardt EL; Ouma A; Edmonson MN; Patel A; Nakitandwe J; Pappo AS; Azzato EM; Shurtleff SA; Ellison DW; Downing JR; Hudson MM; Robison LL; Santana V; Newman S; Zhang J; Wang Z; Wu G; Nichols KE; Kesserwan CA
Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31604778
[TBL] [Abstract] [Full Text] [Related]
2. Realgar transforming solution as a novel arsenic agent with a lower risk of cardiotoxicity.
Hai Y; Song P; Wang X; Zhao L; Xie Q; Li J; Li Y; Li H
J Pharmacol Sci; 2019 Jun; 140(2):162-170. PubMed ID: 31285125
[TBL] [Abstract] [Full Text] [Related]
3. Realgar transforming solution-induced differentiation of NB4 cell by the degradation of PML/RARα partially through the ubiquitin-proteasome pathway.
Hai Y; Wang X; Song P; Li JY; Zhao LH; Xie F; Tan XM; Xie QJ; Yu L; Li Y; Wu ZR; Li HY
Arch Pharm Res; 2019 Aug; 42(8):684-694. PubMed ID: 31214877
[TBL] [Abstract] [Full Text] [Related]
4. Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
Bhatia S; Krieger V; Groll M; Osko JD; Reßing N; Ahlert H; Borkhardt A; Kurz T; Christianson DW; Hauer J; Hansen FK
J Med Chem; 2018 Nov; 61(22):10299-10309. PubMed ID: 30365892
[TBL] [Abstract] [Full Text] [Related]
5. No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.
Pfirrmann M; Evtimova D; Saussele S; Castagnetti F; Cervantes F; Janssen J; Hoffmann VS; Gugliotta G; Hehlmann R; Hochhaus A; Hasford J; Baccarani M
J Cancer Res Clin Oncol; 2017 May; 143(5):843-850. PubMed ID: 28083711
[TBL] [Abstract] [Full Text] [Related]
6. Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL.
Maurer C; Langerbeins P; Bahlo J; Cramer P; Fink AM; Pflug N; Engelke A; von Tresckow J; Kovacs G; Stilgenbauer S; Wendtner CM; Müller L; Ritgen M; Seiler T; Fischer K; Hallek M; Eichhorst B
Leukemia; 2016 Oct; 30(10):2019-2025. PubMed ID: 27133817
[TBL] [Abstract] [Full Text] [Related]
7. Osteosarcoma in patients with Rothmund-Thomson syndrome.
Zils K; Klingebiel T; Behnisch W; Mueller HL; Schlegel PG; Fruehwald M; Suttorp M; Simon T; Werner M; Bielack S
Pediatr Hematol Oncol; 2015 Feb; 32(1):32-40. PubMed ID: 25551679
[TBL] [Abstract] [Full Text] [Related]
8. Reversal effect of arsenic sensitivity in human leukemia cell line K562 and K562/ADM using realgar transforming solution.
Wang X; Zhang X; Xu Z; Wang Z; Yue X; Li H
Biol Pharm Bull; 2013; 36(4):641-8. PubMed ID: 23358330
[TBL] [Abstract] [Full Text] [Related]
9. Multiple malignant diseases in a patient with Rothmund-Thomson syndrome with recql4 mutations: Case report and literature review.
Simon T; Kohlhase J; Wilhelm C; Kochanek M; De Carolis B; Berthold F
Am J Med Genet A; 2010 Jun; 152A(6):1575-9. PubMed ID: 20503338
[TBL] [Abstract] [Full Text] [Related]
10. Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy.
Wilking N; Lidbrink E; Wiklund T; Erikstein B; Lindman H; Malmström P; Kellokumpu-Lehtinen P; Bengtsson NO; Söderlund G; Anker G; Wist E; Ottosson S; Salminen E; Ljungman P; Holte H; Nilsson J; Blomqvist C; Bergh J
Ann Oncol; 2007 Apr; 18(4):694-700. PubMed ID: 17301072
[TBL] [Abstract] [Full Text] [Related]
11. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
Bergh J; Wiklund T; Erikstein B; Lidbrink E; Lindman H; Malmström P; Kellokumpu-Lehtinen P; Bengtsson NO; Söderlund G; Anker G; Wist E; Ottosson S; Salminen E; Ljungman P; Holte H; Nilsson J; Blomqvist C; Wilking N
Lancet; 2000 Oct; 356(9239):1384-91. PubMed ID: 11052580
[TBL] [Abstract] [Full Text] [Related]
12. Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401.
Bergh J; Wiklund T; Erikstein B; Fornander T; Bengtsson NO; Malmström P; Kellokumpu-Lehtinen P; Anker G; Bennmarker H; Wilking N
Ann Oncol; 1998 Apr; 9(4):403-11. PubMed ID: 9636831
[TBL] [Abstract] [Full Text] [Related]
